Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 9, Issue 9, 2009, Pages 537-545

  Burch, Jane ^a   Corbett, Mark ^a   Stock, Christian ^a   Nicholson, Karl ^b   Elliot, Alex J ^c   Duffy, Steven ^a   Westwood, Marie ^a   Palmer, Stephen ^a   Stewart, Lesley ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; ZANAMIVIR;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; HEALTH HAZARD; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; META ANALYSIS; PANDEMIC; PNEUMONIA; POPULATION RISK; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ADULT; ANTIVIRAL AGENTS; GREAT BRITAIN; HUMANS; INFLUENZA, HUMAN; OSELTAMIVIR; TREATMENT OUTCOME; ZANAMIVIR;

EID: 68649115290     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70199-9     Document Type: Review

References (62)

1. Elliot A.J., and Fleming D.M. Surveillance of influenza-like illness in England and Wales during 1966-2006. Euro Surveill 11 (2006) 249-250
2. Pitman R.J., Melegaro A., Gelb D., Siddiqui M.R., Gay N.J., and Edmunds W.J. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 54 (2007) 530-538
3. Fleming D.M. The impact of three influenza epidemics on primary care in England and Wales. Pharmacoeconomics 9 suppl 3 (1996) 38-45
4. NICE. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza: technology appraisal guidance no 58 (2003), National Institute for Clinical Excellence, London
5. Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess (in press).
6. Turner D., Wailoo A., Nicholson K., Cooper N., Sutton A., and Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 7 (2003) 1-182
7. Casella G., and Berger R.L. Statistical inference. 2nd edn. (2002), Duxbury, Pacific Grove, CA
8. Whitehead A. Meta-analysis of controlled clinical trials (2002), John Wiley & Sons Ltd, Chichester
9. Boivin G., Goyette N., Hardy I., Aoki F., Wagner A., and Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 181 (2000) 1471-1474
10. Lalezari J, Klein T, Stapleton J, Elliott M, Flack N, Keene O. The efficacy and safety of inhaled zanamivir of influenza in otherwise healthy and 'high risk' individuals in North America. 21st International Congress of Chemotherapy; Birmingham, UK; July 4-7, 1999. Abstract A:42.
11. Hayden F.G., Osterhaus A.D., Treanor J.J., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections, GG167 Influenza Study Group. N Engl J Med 337 (1997) 874-880
12. Mäkelä M.J., Pauksens K., Rostila T., et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40 (2000) 42-48
13. GlaxoSmithKline. NAIB3002: a double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. http://ctr.glaxowellcome.co.uk/Summary/zanamivir/III_NAIB3002_A.pdf (accessed July 22, 2009).
14. MIST. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352 (1998) 1877-1881
15. Murphy K.R., Eivindson A., Pauksens K., et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstrucitve pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest 20 (2000) 337-349
16. Monto A.S., Fleming D.M., Henry D., et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 180 (1999) 254-261
17. Aoki F.Y., Fleming D.M., Griffin A.D., Lacey L.A., Edmundson S., and on behalf of the Zanamivir Study Group. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Pharmacoeconomics 17 (2000) 187-195
18. GlaxoSmithKline. NAIB3001: a double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. http://ctr.glaxowellcome.co.uk/Summary/zanamivir/III_NAIB3001.pdf (accessed July 22, 2009).
19. FDA Center for Drug Evaluation and Research. Relenza (zanamivir dry powder for inhalation) for treatment of influenza A and B infections. Medical review (1999), Food and Drug Administration, Rockville, MD. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-036-s001_relenza_medr.pdf (accessed July 22, 2009).
20. Puhakka T., Lehti H., Vainionpaa R., et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 35 (2003) 52-58
21. GlaxoSmithKline. NAI30015: a double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. http://ctr.glaxowellcome.co.uk/Summary/zanamivir/III_NAI30015.pdf (accessed July 22, 2009).
22. GlaxoSmithKline. NAI30020: a double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled Zanamivir (10 mg bd via Diskhaler), for 5 days, in high risk patients with symptomatic Influenza A and/or B infection. http://ctr.glaxowellcome.co.uk/Summary/zanamivir/III_NAI30020.pdf (accessed July 22, 2009).
23. Hedrick J.A., Barzilai A., Behre U., et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19 (2000) 410-417
24. GlaxoSmithKline. NAI30009: a double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12. http://ctr.glaxowellcome.co.uk/Summary/zanamivir/III_NAI30009.pdf (accessed July 22, 2009).
25. GlaxoSmithKline. NAI30012: a double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in subjects aged = 65 years. http://ctr.glaxowellcome.co.uk/Summary/zanamivir/III_NAI30012.pdf (accessed July 22, 2009).
26. Li L., Cai B., Wang M., and Zhu Y. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J 116 (2003) 44-48
27. Nicholson K.G., Aoki F.Y., Osterhaus A.D., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355 (2000) 1845-1850
28. FDA Center for Drug Evaluation and Research. Oseltamivir (Tamiflu) for treatment of uncomplicated acute illness due to influenza infection in adults who have been symptomatic for no more than two days, medical review (1999), Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/foi/nda/99/21087_Tamiflu_medr_P1.pdf (accessed April 18, 2008).
29. Treanor J.J., Hayden F.G., Vrooman P.S., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283 (2000) 1016-1024
30. Robson R, Saiedabadi N, Ward P. Oral oseltamivir reduces the duration of influenza illness by 2·7 days in previously healthy adults. 9th International Congress on Infectious Diseases; Buenos Aires, Argentina; Apr 10-13, 2000.
31. Tan W., Hou J., Chen X., Xiong H., Li X.Q., and Zhang H. A randomized, double-blinded and controlled clinical evaluation of oseltamivir in the treatment of influenza. Chin J Clin Med 9 (2002) 528-531 (in Chinese).
32. Kashiwagi S., Kudoh S., Watanabe A., and Yoshimura I. Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza-placebo-controlled double-blind multicenter phase III trial. Kansenshogaku Zasshi 74 (2000) 1044-1061 (in Japanese).
33. Deng W.W., Li Q.Y., Zhong N.S., and for the Oseltamivir in the treatment of suspected influenza patients study group. A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients. Zhonghua Yi Xue Za Zhi 84 (2004) 2132-2136 (in Chinese).
34. Martin C., Mahoney P., and Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. Int Congr Ser 1219 (2001) 807-811
35. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness and is safe in patients with chronic cardiac and/or respiratory disease. World Congress on Lung Health; Florence, Italy; Aug 30 to Sep 3, 2000.
36. Johnston S.L., Ferrero F., Garcia M.L., and Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 24 (2005) 225-232
37. Roche. A double-blind, randomized, stratified, placebo-controlled study of oseltamivir in the treatment of influenza in children with asthma, NV16871. http://www.roche-trials.com/patient/trialresults/stur40.html (accessed July 22, 2009).
38. Sylvester R.J., Pinedo H.M., De Pauw M., et al. Quality of institutional participation in multicenter clinical trials. N Engl J Med 305 (1981) 852-855
39. Ioannidis J.P., Dixon D.O., McIntosh M., Albert J.M., Bozzette S.A., and Schnittman S.M. Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. Control Clin Trials 20 (1999) 253-266
40. Department of Health. Influenza. In: Salisbury D., Ramsay M., and Noakes K. (Eds). Immunisation against infectious disease-the Green Book (2006), Stationery Office, London 185-200
41. Kawai N., Ikematsu H., Iwaki N., et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 40 (2005) 1309-1316
42. Aoki F.Y., Macleod M.D., Paggiaro P., et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51 (2003) 123-129
43. Low D. Reducing antibiotic use in influenza: challenges and rewards. Clin Microbiol Infect 14 (2008) 298-306
44. McNulty C.A., and Johnson A.P. The European antibiotic awareness day. J Antimicrob Chemother 62 (2008) 853-854
45. Keech M., and Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 26 (2003) 911-924
46. Carrat F., Deshayes J., Goderel I., Pannetier G., Lazarovici C., and Valleron A.-J. Factors associated with intensity of symptoms in patients seeking medical advice for flu. Int Congr Ser 1263 (2004) 308-311
47. Goddard N.L., Kyncl J., and Watson J.M. Appropriateness of thresholds currently used to describe influenza activity in England. Commun Dis Public Health 6 (2003) 238-245
48. Fleming D.M., Zambon M., Bartelds A.I., and de Jong J.C. The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. Eur J Epidemiol 15 (1999) 467-473
49. GlaxoSmithKline. Patient information leaflet on fluarix (influenza) 2008/2009 vaccine. http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=3704 (accessed July 22, 2009).
50. Nichol K.L. Efficacy and effectiveness of influenza vaccination. Vaccine 26 suppl 4 (2008) D17-D22
51. Winchester C.C., Macfarlane T.V., Thomas M., and Price D. Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care. Chest 135 (2009) 1163-1172
52. Belongia E.A., Kieke B.A., Donahue J.G., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199 (2009) 159-167
53. Ndifon W., Dushoff J., and Levin S.A. On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness. Vaccine 27 (2009) 2447-2452
54. Allsup S., Haycox A., Regan M., and Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 23 (2004) 639-645
55. Turner D.A., Wailoo A.J., Cooper N.J., Sutton A.J., Abrams K.R., and Nicholson K.G. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 24 (2006) 1035-1043
56. Tappenden P., Jackson R., Cooper K., et al. Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of existing guidance no 67). Health Technol Assess 13 (2009) 1-268
57. WHO. Influenza A(H1N1) virus resistance to oseltamivir-2008/2009 influenza season, northern hemisphere (2009), World Health Organization, Geneva. http://www.who.int/csr/disease/influenza/H1N1webupdate20090318%20ed_ns.pdf (accessed July 22, 2009).
58. Dharan N.J., Gubareva L.V., Meyer J.J., et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 (2009) 1034-1041
59. ECDC. Emergence of seasonal influenza viruses type A/H1N1 with oseltamivir resistance in some European Countries at the start of the 2007-8 influenza season: interim ECDC Risk Assessment-January 27th 2008 (2008), European Centre for Disease Prevention and Control, Stockholm. http://ecdc.europa.eu/pdf/080127_os.pdf (accessed July 22, 2009).
60. Reece P.A. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79 (2007) 1577-1586
61. Hauge S.H., Blix H.S., Borgen K., Hungnes O., Dudman S.G., and Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol J 6 (2009) 54
62. CDC. Rapid diagnostic testing for influenza: information for clinical laboratory directors. http://www.cdc.gov/flu/professionals/diagnosis/rapidlab.htm (accessed April 18, 2008).